Roche invests in innovation as it hires early R&D head from Sanford-Burnham
This article was originally published in Scrip
The recruitment of John Reed from the Sanford-Burnham Medical Research Institute in San Diego as the head of Roche Pharma Research and Early Development (pRED) appears to be a strategic hire in line with Roche's plans for adding innovative drug and diagnostic technology from external sources to its internal research and development pipeline.
You may also be interested in...
A Phase I study for allogeneic therapy UCARTCS1A was put on clinical hold after a patient died. High dosing and double exposure to cyclophosphamide pre-conditioning may have played a role.
After accelerated approval in the US in April based on Phase II response rates, the company will seek full approval later this year based on a tripling of progression-free survival in a Phase III trial.
Public Company Edition: Drug developers continue to take advantage of investors’ preference for biotechnology investments, with CRISPR, Acceleron and BioNTech raising massive sums. The wealth isn’t spreading to everyone, however, as DBV Technologies is restructuring and cutting jobs.